Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206020 | 1.00 | KDM1A (0.31) | KDM1AKCNH2KDM1B | |
| SCHEMBL1643790 | 0.81 | — | — | |
| SCHEMBL18101283 | 0.79 | ACHE (0.30) | — | |
| SCHEMBL29966228 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL23166979 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL2487490 | 0.77 | KDM1A (0.39) | KDM1AKCNH2KDM1B | |
| SCHEMBL18721392 | 0.75 | ACHE (0.31) | — | |
| SCHEMBL13212278 | 0.75 | HDAC4 (0.33) | — | |
| SCHEMBL5735519 | 0.75 | ALDH1A1 (0.36) | KDM1AKCNH2KDM1B | |
| SCHEMBL29636024 | 0.75 | KDM1A (0.33) | KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368620-A1 | ARNT Degrading Compounds and Uses Thereof | CELGENE CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4480482-A2 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | AbbVie Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | ABBVIE INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4249073-B1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-3107900-B1 | 5-BENZYLISOQUINOLEINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | SERVIER LAB (FR) | 2017-11-15 | — | — | EP | disclosed |
| US-9809553-B2 | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-9783735-B2 | Liquid crystal display device and liquid crystal composition used therefor | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-10-10 | — | — | US | disclosed |
| US-9783735-B2 | Liquid crystal display device and liquid crystal composition used therefor | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-10-10 | — | — | US | disclosed |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-05-18 | — | — | US | disclosed |
| EP-3107900-A1 | DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Les Laboratoires Servier (FR) | 2016-12-28 | — | — | EP | disclosed |
| US-20160304783-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL COMPOSITION USED THEREFOR | DONGJIN SEMICHEM CO., LTD. (KR) | 2016-10-20 | — | — | US | disclosed |
| US-20160304783-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL COMPOSITION USED THEREFOR | DONGJIN SEMICHEM CO., LTD. (KR) | 2016-10-20 | — | — | US | disclosed |
| WO-2015124877-A1 | DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | LES LABORATOIRES SERVIER (FR) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | BTK, TYMP, LYN | KDM1A 568/4885KCNH2 3662/4885KDM1B 386/4885 |
| US-20160304783-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL COMPOSITION USED THEREFOR | SLC39A11, CYP4F11, WEE1 | KDM1A 3795/4885KCNH2 3407/4885KDM1B 3636/4885 |
| US-12384808-B2 | Modulators of TNF-α activity | TNF, NFKBIA, TNFRSF1A | KDM1A 3878/4885KCNH2 4764/4885KDM1B 4493/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | KDM1A 2276/4885KCNH2 896/4885KDM1B 3534/4885 |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MYLK, MYLK2, MYLK3 | KDM1A 3673/4885KCNH2 3203/4885KDM1B 3352/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | KDM1A 4193/4885KCNH2 4777/4885KDM1B 4613/4885 |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | KDM1A 568/4885KCNH2 3130/4885KDM1B 578/4885 |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | BTK, TYMP, LYN | KDM1A 568/4885KCNH2 3662/4885KDM1B 386/4885 |
| US-20250368620-A1 | ARNT Degrading Compounds and Uses Thereof | ARNT, AHR, NR1H2 | KDM1A 2637/4885KCNH2 4678/4885KDM1B 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.